Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals

Clinical Infectious Diseases(2023)10.1093/cid/ciad696Source: DataRank Database

Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals is a research paper published in Clinical Infectious Diseases (2023). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access35 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 5.89)OA: hybridTopics (35)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (37)

Jessica E Biddle ORCID,H. Keipp Talbot ORCID,Kerry Grace Morrissey ORCID,Melissa S. Stockwell ORCID,Yvonne Maldonado ORCID

Live enrichment

PubMed:37963102 PMC:PMC11090981 OpenAlex:https://openalex.org/W4388666940

CDC

Grant: 75D30121C11656

CDC

Grant: 75D30121C11571

RVTN

Grant: 75D30121C11656)

NIAID NIH HHS

Grant: K24 AI148459

Intramural CDC HHS

Grant: CC999999

Vanderbilt University Medical Center

Trustees of Columbia University

FWCI

5.89

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: public-domain

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad696/53404202/ciad696.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad696/53404202/ciad696.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad696/53929004/ciad696.pdf

publisherhttps://academic.oup.com/cid/article-pdf/78/5/1175/57638359/ciad696.pdf

journalhttps://doi.org/10.1093/cid/ciad696

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

MeSH Terms

COVID-19SARS-CoV-2COVID-19 Drug TreatmentAdultAgedAntiviral AgentsFemaleHumansMaleMiddle AgedOutpatientsRitonavirViral LoadPropensity Score

Keywords

MedicineRitonavirInternal medicineAmbulatoryViral loadCoronavirus disease 2019 (COVID-19)Severity of illnessYoung adultGastroenterologyHuman immunodeficiency virus (HIV)ImmunologyDiseaseAntiretroviral therapyAntiviral treatmentViral loadsSymptomsReboundSars-cov-2

Sustainable Development Goals

SDG 0: Good health and well-being